Novavax (NVAX) reported $1.1B in revenue for fiscal 2025, +64.7% year on year. That ranks #1703 by revenue among 2853 SEC filers and #156 in Healthcare. Net income was $440M, a net margin of 39.2%. Revenue has grown 36.3% a year on average since 2011 ($14.7M then). The fiscal 2025 balance sheet shows $1.2B in total assets, $241M in cash and $244M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.1B | +64.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $453M | +$702M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $440M | +$628M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$245M | −$157M | FY20252025-12-31 |
| Capital expenditurePaymentsForCapitalImprovements | $5.6M | −57.4% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | −24.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$128M | +$496M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $241M | −54.6% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $244M | — | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $140M | −$9.5M | Open → |
| Q2 20262026-06-30 | $56.7M | −$53.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 3 of 161 companies compared | 39.2% | |
| Operating marginRank 5 of 160 companies compared | 40.3% | |
| R&D as share of revenueRank 15 of 102 companies compared | 30.5% | |
| Cash as share of revenueRank 47 of 160 companies compared | 21.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Novavax Inc
- Ticker
- NVAX
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001000694
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Bio-TechneTECH | $1.2B | $73.4M |
| Trulieve CannabisTRLV | $1.2B | −$116M |
| Sotera HealthSHC | $1.2B | $77.9M |
| NovavaxNVAX | $1.1B | $440M |
| Prestige Consumer HealthcarePBH | $1.1B | $190M |
| EmbectaEMBC | $1.1B | $95.4M |
| Acadia PharmaceuticalsACAD | $1.1B | $391M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Novavax — Key figures |url=https://companiesranked.com/en/company/novavax |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Novavax — Key figures. CompaniesRanked. https://companiesranked.com/en/company/novavaxBibTeX
@misc{companiesranked-en-company-novavax-2026,
author = {{CompaniesRanked}},
title = {{Novavax — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/novavax}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001000694-26-000007 · February 26, 2026
{{cite web |title=Novavax — Key figures — 10-K (0001000694-26-000007) |url=https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.